SCHEMBL3311276

SCHEMBL3311276

CC(C)CCN1CCC(Nc2ccc3cnccc3c2)CC1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 7/20 0.51
ROCK1 Q13464 7/20 0.51
NAMPT P43490 1/20 0.45
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA4 P22748 1/20 0.42
CA5A P35218 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA13 Q8N1Q1 1/20 0.42
CA14 Q9ULX7 1/20 0.42
AKT1 P31749 1/20 0.41
PRMT3 O60678 5/20 0.41
DYRK1A Q13627 2/20 0.41
WNT1 P04628 1/20 0.41
DDX3X O00571 1/20 0.40
CCR2 P41597 1/20 0.40
KCNH2 Q12809 1/20 0.39
PABPC1 P11940 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3315792 0.94 ROCK2 (0.58) ROCK2ROCK1NAMPTAKT1CCR2
SCHEMBL3315893 0.94 ROCK2 (0.58) ROCK2ROCK1NAMPTAKT1CCR2
SCHEMBL3319897 0.90 ROCK2 (0.51) ROCK2ROCK1NAMPTPRMT3DDX3X
SCHEMBL3312007 0.90 ROCK2 (0.61) ROCK2ROCK1NAMPTCA12CA1
SCHEMBL3312503 0.88 ROCK2 (0.67) ROCK2ROCK1CCR2
SCHEMBL3312498 0.88 ROCK2 (0.67) ROCK2ROCK1CCR2
SCHEMBL3316792 0.87 ROCK2 (0.54) ROCK2ROCK1NAMPTAKT1PRMT3
SCHEMBL3316796 0.87 ROCK2 (0.54) ROCK2ROCK1NAMPTAKT1PRMT3
SCHEMBL3311852 0.87 ROCK2 (0.60) ROCK2ROCK1CA12CA1CA2
SCHEMBL3312264 0.85 ROCK2 (0.52) ROCK2ROCK1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-8748614-B2 Substituted isoquinoline and isoquinolinone derivatives SANOFI (FR) 2014-06-10 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives SANOFI-AVENTIS (FR) 2010-04-29 US disclosed
EP-2114920-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES Sanofi-Aventis (FR) 2009-11-11 EP disclosed
WO-2008077552-A1 SUBSTITUTED ISOQUINOLINE AND ISOQUINOLINONE DERIVATIVES SANOFI-AVENTIS (FR) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105650-A1 Substituted isoquinoline and isoquinolinone derivatives MYLK2, MYLK, MYLK3 ROCK2 6/4885ROCK1 5/4885NAMPT 2437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.